US Bancorp DE trimmed its holdings in shares of STERIS plc (NYSE:STE - Free Report) by 17.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,524 shares of the medical equipment provider's stock after selling 5,758 shares during the period. US Bancorp DE's holdings in STERIS were worth $6,433,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in STE. Bleakley Financial Group LLC boosted its stake in shares of STERIS by 8.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider's stock worth $407,000 after acquiring an additional 134 shares in the last quarter. Russell Investments Group Ltd. increased its stake in STERIS by 8.3% in the 1st quarter. Russell Investments Group Ltd. now owns 58,841 shares of the medical equipment provider's stock worth $13,235,000 after purchasing an additional 4,494 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in STERIS by 3.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 106,346 shares of the medical equipment provider's stock worth $23,909,000 after buying an additional 3,342 shares during the period. BDF Gestion purchased a new stake in STERIS during the second quarter valued at about $2,644,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of STERIS by 7.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider's stock worth $390,880,000 after buying an additional 120,616 shares during the period. Institutional investors and hedge funds own 94.69% of the company's stock.
Shares of NYSE:STE opened at $225.18 on Monday. The business has a fifty day simple moving average of $233.72 and a 200 day simple moving average of $227.23. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. STERIS plc has a 1 year low of $195.47 and a 1 year high of $248.24. The firm has a market cap of $22.21 billion, a price-to-earnings ratio of 55.88 and a beta of 0.85.
STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.16. The business had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm's revenue was down .4% on a year-over-year basis. During the same period in the previous year, the company earned $2.00 EPS. As a group, sell-side analysts predict that STERIS plc will post 9.02 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS's dividend payout ratio is presently 56.58%.
A number of equities research analysts have recently issued reports on STE shares. JMP Securities restated a "market outperform" rating and set a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Thursday, August 8th. Stephens reaffirmed an "overweight" rating and issued a $260.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Piper Sandler raised STERIS from a "neutral" rating to an "overweight" rating and upped their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Finally, StockNews.com lowered STERIS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, STERIS presently has an average rating of "Moderate Buy" and an average target price of $253.00.
Read Our Latest Research Report on STE
In other STERIS news, Director Christopher S. Holland sold 473 shares of the business's stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now owns 582 shares of the company's stock, valued at $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Michael J. Tokich sold 23,332 shares of the firm's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Christopher S. Holland sold 473 shares of the business's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now directly owns 582 shares of the company's stock, valued at approximately $139,493.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.